InMed Pharmaceuticals(INM)
$15.61+3.41 (+27.94%)
INM
InMed Pharmaceuticals stock forecast
$15.61
At close:+3.41 (+27.94%)
Want to see INM full AI Analyst Report?
InMed Pharmaceuticals (INM) Stock Forecast & Price Target
397 Followers
INM Analyst Ratings
Strong Buy
4Buy0Hold0Sell
Based on 4 analysts giving stock ratings to InMed Pharmaceuticals in the past 3 months
INM Stock 12 Month Forecast
Average Price Target
$34.00▲(117.82% Upside)Based on 4 Wall Street analysts offering 12 month price targets for InMed Pharmaceuticals in the last 3 months. The average price target is $34.00 with a high forecast of $42.00 and a low forecast of $30.00. The average price target represents a 117.82% change from the last price of $15.61.
Past 12 Months12 Month ForecastJan2026Oct2026
High$42.00
Average$34.00
Low$30.00
Highest Price TargetHighest$42.00Average Price Target$34.00Lowest Price TargetLowest$30.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Tyler Van Buren | TD Cowen | ― | buy | ― | Initiated | 11/11/26 | ||
| Paul Matteis | Stifel Nicolaus | $30 | buy | 92.20%Upside | Initiated | 11/10/26 | ||
| Andrew Tsai | Jefferies | $30 | buy | 92.20%Upside | Initiated | 11/10/26 | ||
 Unknown AnalystNot Ranked | Guggenheim | $42 | buy | 169.08%Upside | Initiated | 11/09/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Tyler Van BurenTD Cowen | BuyInitiated | 11/11/26 | ― | ||
| Paul MatteisStifel Nicolaus | BuyInitiated$30 | 11/10/26 | 92.20%Upside | ||
| Andrew TsaiJefferies | BuyInitiated$30 | 11/10/26 | 92.20%Upside | ||
| Unknown AnalystGuggenheimNot Ranked | BuyInitiated$42 | 11/09/26 | 169.08%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
INM Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 3 |
| Buy | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 0 | 0 | 0 | 4 |
In the current month, INM has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. INM average Analyst price target in the past 3 months is 34.00.
INM Financial Forecast
Consensus$-0.43
INM Earnings Forecast
Next quarter’s earnings estimate for INM is -$0.43 with a range of ― to ―. The previous quarter’s EPS was -$0.43. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
Consensus$0.00
INM Sales Forecast
Next quarter’s sales forecast for INM is $0 with a range of ― to ―. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
INM Stock Forecast FAQ
What is INM’s average 12-month price target, according to analysts?
Based on analyst ratings, InMed Pharmaceuticals’s 12-month average price target is $34.00.
What is INM’s upside potential, based on the analysts’ average price target?
InMed Pharmaceuticals has 117.82% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INM a Buy, Sell or Hold?
InMed Pharmaceuticals has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is InMed Pharmaceuticals’s price target?
The average price target for InMed Pharmaceuticals is $34.00. This is based on 4 12-month price targets, issued in the past 3 months. The highest analyst price target is $42.00, the lowest forecast is $30.00. The average price target represents a 117.82% increase from the current price of $15.609.
What do analysts say about InMed Pharmaceuticals?
InMed Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of INM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
